Company
Every investor coverage indicates participated in a round POINT Biopharma raised.
Companies POINT Biopharma acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Henrik Ørum | Chief Scientific Officer | Brandon BioCatalyst portfolio |
Stories naming POINT Biopharma. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Brisbane radiopharmaceutical developer AdvanCell has closed an oversubscribed Series D round, led by Ally Bridge Group and Alpha Wave with several institutional investors returning, to fund late-stage prostate cancer trials and US manufacturing.
New Zealand biotech Amaroq Therapeutics reported early progress toward clinical trials and appointed four leading scientists to its scientific advisory board, strengthening its lncRNA cancer therapy programme.